Theralase Technologies Inc., a company operating within the Health Care Equipment & Supplies sector, is based in Toronto, Canada. The company is primarily engaged in the design, development, manufacturing, and distribution of therapeutic medical lasers. These lasers are utilized in photo-dynamic medical therapy, focusing on applications such as pain management, treatment of musculo-skeletal arthritic and rheumatoidal disorders, and wound care, including the healing of bone fractures.
As of December 30, 2025, Theralase Technologies Inc.’s stock was trading at CAD 0.165 on the TSX Venture Exchange. The company’s stock has experienced fluctuations over the past year, with a 52-week high of CAD 0.34 on January 5, 2025, and a 52-week low of CAD 0.145 on December 14, 2025. The market capitalization of Theralase Technologies Inc. stands at CAD 43,710,000.
In terms of financial metrics, Theralase Technologies Inc. exhibits a negative price-to-earnings (P/E) ratio of -9.25, reflecting the company’s current lack of profitability. Additionally, the company’s price-to-book ratio is 37.64, indicating that the market values the company at a significant premium relative to its book value. This valuation suggests investor confidence in the company’s future potential despite its current financial performance.
In recent developments, Theralase Technologies Inc. has remained relatively quiet, with no significant announcements beyond a $1.3 million non-brokered private placement reported on December 23, 2025. The company’s stock closed at CAD 0.16 on December 30, 2025, within its annual trading range.
For further information about Theralase Technologies Inc. and its offerings, interested parties can visit the company’s website at www.theralase.com .
